Efficacy and Safety of Extended-Release Quetiapine Fumarate in Youth with Bipolar Depression: An 8 Week, Double-Blind, Placebo-Controlled Trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Quetiapine is an atypical antipsychotic with demonstrated efficacy in the treatment of adolescent schizophrenia and pediatric bipolar mania. Large, placebo-controlled studies of interventions in pediatric bipolar depression are lacking. The current study investigated the efficacy and safety of quetiapine extended-release (XR) in patients 10-17 years of age, with acute bipolar depression. METHODS: This multicenter, double-blind, randomized, placebo-controlled study investigated quetiapine XR (dose range, 150-300 mg/day) in pediatric outpatients with an American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) diagnosis of bipolar I or bipolar II disorder (current or most recent episode depressed) treated for up to 8 weeks (ClinicalTrials.gov identifier: NCT00811473). The primary study outcome was mean change in Children's Depression Rating Scale-Revised (CDRS-R) total score. Secondary efficacy outcomes included CDRS-R-based response and remission rates. RESULTS: Of 193 patients randomized to treatment, 144 patients completed the study (75.3% of quetiapine XR group [n=70]; 74.0% of placebo group [n=74]). Least squares mean changes in CDRS-R total score at week 8 were: -29.6 (SE, 1.65) with quetiapine XR and -27.3 (SE, 1.60) with placebo, a between-treatment group difference of -2.29 (SE, 1.99; 95% CI, -6.22, 1.65; p=0.25; mixed-model for repeated measures analysis). Rates of response and remission did not differ significantly between treatment groups. The safety profile of quetiapine XR was broadly consistent with the profile reported previously in adult studies of quetiapine XR and pediatric studies of quetiapine immediate-release (IR). Potentially clinically significant elevations in clinical chemistry values included triglycerides (9.3%, quetiapine XR; 1.4%, placebo group) and thyroid stimulating hormone (4.7%, quetiapine XR; 0%, placebo group). An adverse event potentially related to diabetes mellitus occurred in 3.3% of the quetiapine XR versus no adverse events in the placebo group. CONCLUSIONS: Quetiapine XR did not demonstrate efficacy relative to placebo in this 8 week study of pediatric bipolar depression. Quetiapine XR was generally safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 2×
“…and randomization (baseline), after a 7–28 day washout of all current psychotropic medications (with the exception of psychotropics in patients with attention-deficit/ hyperactivity disorder [ADHD]; described subsequently) (Young et al. 1978; Poznanski et al. 1979; Poznanski and Mokros 1996).”
BackgroundMethodPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 4×
“Adverse events, YMRS score, C-SSRS, weight, and vital signs were reported at screening, baseline, and weekly visits up to week 8.”
MethodInfluentialSpearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 1×
“…of quetiapine has proven efficacy in the treatment of adults with schizophrenia, bipolar mania, and bipolar depression (Buckley 2004; Vieta et al. 2005; Thase et al. 2006; Calabrese et al. 2005; McElroy et al. 2010; 1Johns Hopkins Medicine and the Kennedy Krieger Institute, Baltimore, Maryland.”
BackgroundThase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559 · cited 1×
“…of quetiapine has proven efficacy in the treatment of adults with schizophrenia, bipolar mania, and bipolar depression (Buckley 2004; Vieta et al. 2005; Thase et al. 2006; Calabrese et al. 2005; McElroy et al. 2010; 1Johns Hopkins Medicine and the Kennedy Krieger Institute, Baltimore, Maryland.”
BackgroundYoung, A. H., McElroy, S. L., Bauer, M., Philips, N., Chang, W., Olausson, B., Paulsson, B., Brecher, M., & EMBOLDEN I (Trial 001) Investigators (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04995gre · Cited by 390
McElroy, S. L., Weisler, R. H., Chang, W., Olausson, B., Paulsson, B., Brecher, M., Agambaram, V., Merideth, C., Nordenhem, A., Young, A. H., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04942gre · Cited by 328 · cited 1×
“…of quetiapine has proven efficacy in the treatment of adults with schizophrenia, bipolar mania, and bipolar depression (Buckley 2004; Vieta et al. 2005; Thase et al. 2006; Calabrese et al. 2005; McElroy et al. 2010; 1Johns Hopkins Medicine and the Kennedy Krieger Institute, Baltimore, Maryland.”
BackgroundBridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256 · cited 7×
“Variability in the placebo response rate has largely explained the difference between ‘‘positive’’ and ‘‘negative’’ trials of medications in MDD (Bridge et al. 2009).”
BackgroundResultInfluentialOpen-Label Lithium for the Treatment of Adolescents With Bipolar Depression
PATEL, N. C., DELBELLO, M. P., BRYAN, H. S., ADLER, C. M., KOWATCH, R. A., STANFORD, K., & STRAKOWSKI, S. M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000194569.70912.a7 · Cited by 157 · cited 1×
“Age-specific open-label trials have described improvements in depressive symptoms from baseline with the mood stabilizers lithium, extended-release carbamazepine, lamotrigine, and divalproex monotherapy in diverse patient groups (Patel et al. 2006; Biederman et al. 2010; Joshi et al. 2010).”
BackgroundSelf-citation
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Townsend, L., Kobak, K., Kearney, C., Milham, M., Andreotti, C., Escalera, J., Alexander, L., Gill, M. K., Birmaher, B., Sylvester, R., et al. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2019.05.009 · Cited by 265
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Detke, H. C., DelBello, M. P., Landry, J., & Usher, R. W. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.12.012 · Cited by 135
Self-citationDelBello, M. P., Goldman, R., Phillips, D., Deng, L., Cucchiaro, J., & Loebel, A. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2017.10.006 · Cited by 135
Self-citationFindling, R. L., Correll, C. U., Nyilas, M., Forbes, R. A., McQuade, R. D., Jin, N., Ivanova, S., Mankoski, R., Carson, W. H., & Carlson, G. A. (2013) · Bipolar Disorders · doi:10.1111/bdi.12042 · Cited by 121
Self-citationGroves, L., Jones, C., Welham, A., Hamilton, A., Liew, A., & Richards, C. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00197-9 · Cited by 20
“9,13,19,20 Several initiatives have been published encouraging clinicians to review and, where appropriate, discontinue medication use for BtC (eg, stopping overmedication of people with a learning disability, autism, or both [STOMP]).”
Background
Metadata
- Authors
- Findling, R. L., Pathak, S., Earley, W. R., Liu, S., & DelBello, M. P.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2014-08
- Volume
- 24
- Issue
- 6
- Pages
- 325-335
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2330720191
- Cited by
- 118
- References
- 11
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.